In some heartening news for the 80% of Americans who will endure lower back pain in their lifetime, researchers have found that an existing drug can be redeployed to target ‘sleeping’, or senescent, ...

A new discovery about osteoporosis suggests a potential treatment target for that brittle-bone disease and for bone loss from rheumatoid arthritis. The findings from University of Virginia School of ...

Osteoporosis is characterized by the weakening of bones, making them fragile and prone to breakage. Excessive activity of 'osteoclasts' or bone-absorbing cells leads to bone loss. Targeting osteoclast ...

Researchers have shown that a naturally occurring peptide (small protein) holds promise as a new therapeutic for osteoporosis and other disorders that feature bone loss, with distinct advantages over ...

Osteoporosis, characterized by an imbalance in bone remodeling, is a growing health concern worldwide. Previous research has highlighted the role of osteogenic CpG oligodeoxynucleotide (iSN40) in ...

During osteoclast differentiation, Ctdnep1 expression remains consistent, yet its depletion results in heightened osteoclast formation and activity. Mechanistically, Ctdnep1 demonstrates a suppressive ...